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Abstract
Objective
To assess the number of individuals visually impaired or blind due to glaucoma and to
examine regional differences and temporal changes in this parameter for the period from
1990 to 2012.
Methods
As part of the Global Burden of Diseases (GBD) Study 2010, we performed a systematic lit-
erature review for the period from 1980 to 2012. We primarily identified 14,908 relevant
manuscripts, out of which 243 high-quality, population-based studies remained after review
by an expert panel that involved application of selection criteria that dwelt on population
representativeness and clarity of visual acuity methods used. Sixty-six specified the propor-
tion attributable to glaucoma. The software tool DisMod-MR (Disease Modeling–Metare-
gression) of the GBD was used to calculate fraction of vision impairment due to glaucoma.
Results
In 2010, 2.1 million (95% Uncertainty Interval (UI):1.9,2.6) people were blind, and 4.2 (95%
UI:3.7,5.8) million were visually impaired due to glaucoma. Glaucoma caused worldwide
6.6% (95% UI:5.9,7.9) of all blindness in 2010 and 2.2% (95% UI:2.0,2.8) of all moderate
and severe visual impairment (MSVI). These figures were lower in regions with younger
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populations (<5% in South Asia) than in high-income regions with relatively old populations
(>10%). From 1990 to 2010, the number of blind or visually impaired due to glaucoma
increased by 0.8 million (95%UI:0.7, 1.1) or 62% and by 2.3 million (95%UI:2.1,3.5) or
83%, respectively. Percentage of global blindness caused by glaucoma increased between
1990 and 2010 from 4.4% (4.0,5.1) to 6.6%. Age-standardized prevalence of glaucoma
related blindness and MSVI did not differ markedly between world regions nor between
women.
Significance
By 2010, one out of 15 blind people was blind due to glaucoma, and one of 45 visually
impaired people was visually impaired, highlighting the increasing global burden of
glaucoma.
Introduction
Previous population-based investigations have shown that glaucoma is one of the most com-
mon, and thus most important, causes for vision loss worldwide [1–34]. Previous estimations
of global burden of glaucoma were based on meta-analyses which did not include studies, as
far as available, from all regions of the world, which did not include all available population-
based studies, which did not assess a change during the last 2 decades, or which mostly
reported on the prevalence of the disease [1–3]. Many of the population-based glaucoma stud-
ies did not report on the number of people blind or visually impaired due glaucoma. For public
health purposes, however, the number of patients functionally affected is more important than
the number of patients with any stage of the disease. For the individual patient and thus for the
society, the burden of a disease is more important than just the presence of a disease including
its early stages. We therefore conducted this meta-analysis of all available population-based
studies performedworldwide within the last two decades to estimate the number of people
affected by blindness (defined as presenting visual acuity<3/60) and moderately to severe
visual impairment (MSVI; presenting visual acuity<6/18,3/60) due to glaucoma, to assess
changes in that figures during the period from 1990 to 2010, to examine regional differences in
the prevalence of glaucoma related blindness and MSVI, and finally to compare the number of
blind and visually impaired people with glaucoma with the number of people blind and visually
impaired due to other diseases.
Methods
In a systemic literature research we used the systems of Medline, Embase and theWHO
(World Health Organization) library information system to search for articles on vision loss
and published in the period between 1980 and 2012. The methodology for this systematic
review is described in Fig 1 as a PRISMA (Preferred Reporting Items for Systematic Reviews
and Meta-Analyses) flowchart with a PRISMA checklist in S1 Appendix. The search strategy is
presented in S2 Appendix. Out of primarily identified 14,908 relevant manuscripts, we selected
243 high-quality, population-based studies after review by an expert panel. The latter involved
application of selection criteria that were based on population representativeness and clarity of
visual acuity methods used. As described in detail recently, search terms included concepts to
describe “blindness”, “visual impairment”, “population”, “eye”, “survey”, and a list of ocular
disorders [35–37]. Additional unpublished data sources were found by personal
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Fig 1. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flowchart.
doi:10.1371/journal.pone.0162229.g001
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communication with researchers identified in the literature search. Population-based studies
that reported prevalence of visual impairment and blindness disaggregated by cause (128 stud-
ies) provided the basic data to calculate the proportion of blindness and MSVI that were due to
glaucoma, besides other causes such as cataract, macular degeneration, diabetic retinopathy,
trachoma, or undercorrection of refractive error. A full list of data sources used for each cause
has been presented recently (Table B in S3 Appendix) [37]. Two studies per region were avail-
able for 18 of the 21 GBD (Global Burden of Disease) Study regions, while only one study was
identified for Central Europe. Eastern Europe and Central Africa did not have any study with
cause-specific data. No study was identified for 126 of 191 countries. Data were extracted from
published and unpublished reports into an electronic database (Microsoft Excel) by two inves-
tigators working independently with consistency checks in order to minimize data inputting
errors. Extracted data included prevalence of predefined severities of vision loss by age, gender,
country, region, and cause.
Stratifying by age, sex, and geographical region, we estimated trends in causes of vision
impairment and included an analysis of uncertainties. For geographical stratification, we used
the 21 regions defined in the GBD Study [38]. As part of the statistical analysis, we first identi-
fied and accessed the data and then estimated fractions for each cause. We stratified the results
by the severity of vision impairment, sex, age, and region.We finally applied the cause fractions
to the prevalence of all-cause presenting vision impairment [37]. The method has been
described in detail previously [37].
For the statistical analysis, the DiseaseModeling–Metaregression (DisMod-MR)model
from the GBD Study was used to determine the fraction of vision impairment caused by glau-
coma or due to other causes mentioned above (more detailed information is available in S3
Appendix with an explanation of country and regional groupings, Table A, and a full list of
citations of the studies, Table B) [37]. Briefly, the DisMod-MRmodel is a negative binomial
regressionmodel which included the following elements: covariates that predicted the variation
in the true proportion of vision impairment from each disease; fixed effects that adjusted for
definitional differences (e.g. whether the causes of presenting vs. best-corrected vision
impairment were reported); a hierarchical model structure which fitted random intercepts in
individual countries derived from the data observed in the country, in its region, and in other
regions based on the availability and consistency of country- and region-specificdata; age-spe-
cific fixed-effectswhich allowed for a non-linear age pattern; and a fixed effect for data on
males. For the assessment of the fractions of blindness and visual impairment which were
caused by glaucoma, we fitted one DisMod-MRmodel and used three covariates: an indicator
variable which describedwhether the data were for blindness or for MSVI, an indicator vari-
able describingwhether the data were based on presenting visual acuity or best-corrected visual
acuity measurements, and a country-level covariate which reflected the health systems access.
We made two sets of the prediction for glaucoma, one for best-correctedblindness and one for
best-correctedMSVI. Using theWHO reference population, we age-standardized the preva-
lences [39]. We also calculated the numbers of people with vision impairment and blindness
caused by glaucoma. It reflected each region’s population size and age structure.
Results
Blindness caused by glaucoma was found to be present in 2.1 million (95% uncertainty interval
(UI): 1.9, 2.6) people, and MSVI caused by glaucoma was detected for 4.2 million (95%UI: 3.7–
5.8) million individuals (Table 1). Taking into account that overall 32.4 million people were
blind and 191 million people were vision impaired in 2010, glaucoma caused worldwide 6.6%
(95%UI: 5.9, 7.9) of all causes for blindness in 2010 and 2.2% (95%UI: 2.0, 2.8) of all causes for
Vision Loss Due to Glaucoma
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Table 1. Number of people (mean, 95% uncertainty interval) blind (presenting visual acuity <3/60) or visually impaired (MSVI) (presenting visual
acuity <6/18,3/60) due to glaucoma and the age-standardized prevalences (mean, 95% uncertainty interval) in different world regions in 2010.
World Region Blindness / Moderate to
Severe Visual
Impairment (MSVI) by
Glaucoma
Total
Population
2010
Number of People Affected in
2010
Age-Standardized
Prevalence in People
Aged 50+ Years in 2010
Percent of Blindness /
Visual Impairment by
Glaucoma in 2010
Mean
Value
Lower
Value
Upper
Value
Mean
Value
Lower
Value
Upper
Value
World BLIND 6,890,000,000 2,129,010 1,867,190 2,631,980 0.1% 0.1% 0.2% 6.6 (5.9, 7.9)
Asia Pacific,
High Income
BLIND 169,000,000 41,236 21,680 92,060 0.0% 0.0% 0.1% 11.7 (7.1, 18.8)
Asia, Central BLIND 68,800,000 16,146 10,742 26,920 0.1% 0.1% 0.2% 12.0 (8.7, 17.2)
Asia, East BLIND 1,190,000,000 280,664 179,792 445,252 0.1% 0.1% 0.1% 5.4 (3.5, 8.5)
Asia, South BLIND 1,120,000,000 493,126 328,286 787,091 0.2% 0.2% 0.4% 4.7 (3.3, 7.5)
Asia,
Southeast
BLIND 460,000,000 195,036 128,088 280,470 0.2% 0.1% 0.3% 5.6 (4.3, 8.2)
Australasia BLIND 20,500,000 4,359 2,279 12,153 0.0% 0.0% 0.1% 11.3 (6.8, 18.8)
Caribbean BLIND 34,300,000 21,996 13,683 33,690 0.2% 0.1% 0.3% 11.2 (8.0, 15.1)
Europe,
Central
BLIND 122,000,000 40,894 28,224 93,954 0.1% 0.1% 0.2% 12.5 (9.1, 17.0)
Europe,
Eastern
BLIND 222,000,000 79,285 39,916 154,466 0.1% 0.0% 0.2% 13.5 (8.6, 20.6)
Europe,
Western
BLIND 381,000,000 101,391 65,985 159,726 0.0% 0.0% 0.1% 10.6 (8.2, 14.0)
Latin America,
Andean
BLIND 38,600,000 22,996 13,920 35,935 0.3% 0.2% 0.4% 11.7 (7.9, 17.1)
Latin America,
Central
BLIND 166,000,000 118,569 80,675 177,954 0.3% 0.2% 0.4% 13.0 (9.6, 18.2)
Latin America,
Southern
BLIND 48,900,000 28,401 18,116 50,815 0.2% 0.1% 0.3% 12.6 (7.9, 19.3)
Latin America,
Tropical
BLIND 154,000,000 123,409 65,267 262,580 0.3% 0.2% 0.6% 15.5 (9.6, 21.9)
North Africa/
Middle East
BLIND 301,000,000 300,578 216,888 434,025 0.5% 0.4% 0.7% 9.6 (7.5, 13.2)
North
America, High
Income
BLIND 281,000,000 50,464 28,478 90,572 0.0% 0.0% 0.1% 10.7 (7.0, 15.7)
Oceania BLIND 5,814,186 1,375 704 2,694 0.2% 0.1% 0.4% 4.2 (2.5, 7.2)
Sub-Saharan
Africa, Central
BLIND 53,400,000 14,663 7,574 34,857 0.2% 0.1% 0.5% 5.2 (3.4, 8.8)
Sub-Saharan
Africa, East
BLIND 208,000,000 83,252 57,759 121,613 0.3% 0.2% 0.4% 4.0 (3.1, 5.4)
Sub-Saharan
Africa, South
BLIND 52,600,000 21,870 10,551 34,971 0.3% 0.1% 0.4% 7.3 (5.2, 10.4)
Sub-Saharan
Africa, West
BLIND 201,000,000 91,532 64,503 129,601 0.3% 0.2% 0.5% 4.4 (3.4, 5.9)
World MSVI 6,890,000,000 4,209,790 3,693,040 5,808,270 0.3% 0.2% 0.4% 2.2 (2.0, 2.8)
Asia Pacific,
High Income
MSVI 169,000,000 72,451 41,009 284,553 0.1% 0.0% 0.3% 3.7 (2.3, 6.9)
Asia, Central MSVI 68,800,000 42,894 26,157 91,467 0.3% 0.2% 0.6% 3.6 (2.6, 5.4)
Asia, East MSVI 1,190,000,000 519,648 296,002 911,581 0.2% 0.1% 0.3% 1.6 (0.94, 2.5)
Asia, South MSVI 1,120,000,000 1,111,183 707,164 1939,554 0.5% 0.3% 0.8% 1.6 (1.0, 2.6)
Asia,
Southeast
MSVI 460,000,000 330,064 227,354 687,535 0.3% 0.2% 0.7% 1.8 (1.3, 3.0)
Australasia MSVI 20,500,000 14,724 6,098 41,810 0.1% 0.1% 0.4% 3.2 (1.9, 5.9)
(Continued )
Vision Loss Due to Glaucoma
PLOS ONE | DOI:10.1371/journal.pone.0162229 October 20, 2016 5 / 16
MSVI (Table 1) [35]. The percentage of blindness caused by glaucoma varied from<5% in
South Asia, East and West Sub-Saharan Africa, and Oceania, to 15.5% (9.5–21.9%) in Tropical
Latin America.
From the baseline in 1990 to 2010 the number of individuals blind due to glaucoma
increased by 0.8 million (95%UI: 0.7, 1.1) and the number of individuals with MSVI due to
glaucoma increased by 2.3 million (95%UI: 2.1, 3.5) (Tables 1 and 2). If only individuals with
an age of 50+ years were included, the number of people blind due to glaucoma increased from
1.3 million (95%UI: 1.2, 1.6) in 1990 to 2.0 million (95%UI: 1.8, 2.5) in 2010, and the number
of individuals with glaucoma related visual impairment increased from 1.9 million (95%UI:
1.5, 2.3) in 1990 to 3.8 million (95%UI: 3.3, 5.3) in 2010. Compared with 1990, the percentage
of global blindness caused by glaucoma increased from 4.4% (4.0, 5.1) to 6.6% (Tables 1 and 2).
World regions with older populations such as the high-income regions, Southern Latin Amer-
ica, and Central and Eastern Europe, as compared to regions with younger populations showed
a higher percentage of blindness caused by glaucoma in 1990 and in 2010 (Table 1). The
increase in the percentage of global blindness caused by glaucoma from 1990 to 2010 had taken
place in all world regions without major difference between them (Tables 1 and 2).
Table 1. (Continued)
World Region Blindness / Moderate to
Severe Visual
Impairment (MSVI) by
Glaucoma
Total
Population
2010
Number of People Affected in
2010
Age-Standardized
Prevalence in People
Aged 50+ Years in 2010
Percent of Blindness /
Visual Impairment by
Glaucoma in 2010
Mean
Value
Lower
Value
Upper
Value
Mean
Value
Lower
Value
Upper
Value
Caribbean MSVI 34,300,000 52,416 29,454 85,792 0.5% 0.3% 0.9% 4.3 (3.1, 6.4)
Europe,
Central
MSVI 122,000,000 128,461 68,054 265,300 0.3% 0.1% 0.5% 3.9 (2.8, 6.0)
Europe,
Eastern
MSVI 222,000,000 263,377 104,141 592,790 0.3% 0.1% 0.7% 4.5 (2.6, 7.7)
Europe,
Western
MSVI 381,000,000 252,546 171,693 484,709 0.1% 0.1% 0.2% 3.4 (2.5, 4.9)
Latin America,
Andean
MSVI 38,600,000 62,579 36,452 107,134 0.7% 0.4% 1.2% 4.5 (2.9, 7.5)
Latin America,
Central
MSVI 166,000,000 234,065 157,738 362,576 0.6% 0.4% 0.9% 4.6 (3.2, 7.1)
Latin America,
Southern
MSVI 48,900,000 63,187 36,186 139,233 0.3% 0.2% 0.8% 4.0 (2.5, 6.3)
Latin America,
Tropical
MSVI 154,000,000 250,589 132,867 420,236 0.6% 0.3% 1.0% 5.2 (3.2, 8.4)
North Africa/
Middle East
MSVI 301,000,000 414,896 262,711 701,481 0.6% 0.4% 1.1% 3.0 (2.1, 4.7)
North
America, High
Income
MSVI 281,000,000 104,104 68,661 236,663 0.1% 0.0% 0.2% 3.4 (2.3, 5.4)
Oceania MSVI 5,814,186 3,389 1,669 6,666 0.4% 0.2% 0.7% 1.4 (0.85, 2.5)
Sub-Saharan
Africa, Central
MSVI 53,400,000 26,745 14,950 62,450 0.3% 0.2% 0.8% 1.9 (1.2, 3.3)
Sub-Saharan
Africa, East
MSVI 208,000,000 105,933 76,706 160,640 0.3% 0.2% 0.5% 1.5 (1.1, 2.2)
Sub-Saharan
Africa,
Southern
MSVI 52,600,000 24,600 15,208 49,832 0.3% 0.2% 0.5% 2.6 (1.8, 4.0)
Sub-Saharan
Africa, West
MSVI 201,000,000 129,427 92,406 222,330 0.4% 0.3% 0.7% 1.8 (1.3, 2.7)
doi:10.1371/journal.pone.0162229.t001
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Table 2. Number of people (mean, 95% uncertainty interval) blind (presenting visual acuity <3/60) or visually impaired (MSVI) (presenting visual
acuity <6/18,3/60) due to glaucoma and the age-standardized prevalences (mean, 95% uncertainty interval) in different world regions in 1990.
Region Number of People Affected in
1990
Mean Difference in the Number
of People Affected 2010–1990
Age-Standardized
Prevalence in People
Aged 50+ Years in 1990
Percent of Blindness /
Visual Impairment by
Glaucoma in 1990
Mean Lower
Value
Upper
Value
Mean Lower
Value
Upper
Value
Mean Lower
Value
Upper
Value
World BLIND 1316596 1155344 1573536 812414 711846 1058444 0,2% 0,1% 0,2% 4.4 (4.0, 5.1)
Asia Pacific,
High Income
BLIND 24203 13897 48421 17033 7783 43639 0,1% 0,0% 0,1% 9.0 (6.0, 12.8)
Asia, Central BLIND 18340 12302 28142 -2194 -1560 -1222 0,2% 0,1% 0,3% 9.5 (7.3, 12.6)
Asia, East BLIND 220.492 145.928 353.111 60172 33864 92141 0,1% 0,1% 0,2% 3.9 (2.6, 5.8)
Asia, South BLIND 206493 146182 284448 286633 182104 502643 0,2% 0,1% 0,3% 2.4 (1.7, 3.3)
Asia, Southeast BLIND 102470 68890 141352 92566 59198 139118 0,2% 0,2% 0,3% 3.3 (2.6, 4.4)
Australasia BLIND 3240 2152 8014 1119 127 4139 0,1% 0,0% 0,1% 9.6 (7.4, 13.1)
Caribbean BLIND 17989 12161 25590 4007 1522 8100 0,3% 0,2% 0,4% 9.1 (7.3, 11.8)
Europe, Central BLIND 40973 28957 80175 -79 -733 13779 0,1% 0,1% 0,2% 10.2 (7.9, 13.3)
Europe, Eastern BLIND 100223 49413 171479 -20938 -9497 -17013 0,2% 0,1% 0,3% 10.8 (7.7, 15.4)
Europe,
Western
BLIND 104486 76973 166514 -3095 -10988 -6788 0,1% 0,0% 0,1% 9.0 (7.4, 11.3)
Latin America,
Andean
BLIND 12274 7599 18478 10722 6321 17457 0,3% 0,2% 0,5% 6.8 (5.0, 9.6)
Latin America,
Central
BLIND 68707 49116 97253 49862 31559 80701 0,4% 0,3% 0,5% 8.6 (6.7, 11.7)
Latin America,
Southern
BLIND 20923 13656 33269 7478 4460 17546 0,2% 0,1% 0,3% 9.3 (6.6, 12.6)
Latin America,
Tropical
BLIND 64043 33539 128981 59366 31728 133599 0,4% 0,2% 0,8% 9.2 (5.9, 14.0)
North Africa /
Middle East
BLIND 156025 100468 225966 144553 116420 208059 0,6% 0,4% 0,8% 5.6 (4.4, 7.6)
North America,
High Income
BLIND 40330 25890 65139 10134 2588 25433 0,0% 0,0% 0,1% 9.2 (6.7, 11.9)
Oceania BLIND 701 368 1267 674 336 1427 0,2% 0,1% 0,3% 2.8 (2.0, 4.1)
Sub-Saharan
Africa, Central
BLIND 8359 4813 17587 6304 2761 17270 0,2% 0,1% 0,5% 3.3 (2.4, 4.6)
Sub-Saharan
Africa, East
BLIND 42392 30040 56506 40860 27719 65107 0,3% 0,2% 0,4% 2.9 (2.4, 3.6)
Sub-Saharan
Africa, Southern
BLIND 15121 7703 22286 6749 2848 12685 0,4% 0,2% 0,5% 5.4 (4.2, 7.3)
Sub-Saharan
Africa, West
BLIND 49454 34740 67855 42078 29763 61746 0,3% 0,2% 0,5% 2.9 (2.4, 3.8)
World MSVI 1880978 1544298 2335496 2328812 2148742 3472774 0,2% 0,2% 0,3% 1.2 (1.1, 1.5)
Asia Pacific,
High Income
MSVI 33651 19846 95198 38800 21163 189355 0,1% 0,0% 0,2% 2.3 (1.5, 3.5)
Asia, Central MSVI 31447 18045 56188 11447 8112 35279 0,3% 0,2% 0,6% 2.3 (1.8, 3.3)
Asia, East MSVI 267765 139163 435633 251883 156839 475948 0,1% 0,1% 0,2% 0.92 (0.57, 1.5)
Asia, South MSVI 336127 211531 503752 775056 495633 1435802 0,3% 0,2% 0,4% 0.66 (0.47, 0.90)
Asia, Southeast MSVI 116945 78579 175589 213119 148775 511946 0,2% 0,2% 0,4% 0.83 (0.65, 1.1)
Australasia MSVI 9028 4311 20390 5696 1787 21420 0,2% 0,1% 0,3% 2.4 (1.7, 3.4)
Caribbean MSVI 31364 16368 43633 21052 13086 42159 0,5% 0,3% 0,8% 3.0 (2.2, 4.1)
Europe, Central MSVI 88984 43131 155615 39477 24923 109685 0,3% 0,1% 0,5% 2.5 (1.9, 3.3)
Europe, Eastern MSVI 206804 96231 351954 56573 7910 240836 0,3% 0,1% 0,5% 2.7 (1.8, 4.2)
(Continued )
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Age-standardized prevalence of glaucoma related blindness was worldwide 0.1% (95%UI:
0.1, 02) in adults aged 50+ years in 2010, and the age-standardized prevalence of MSVI caused
by glaucoma was worldwide 0.3% (95%UI: 0.2, 0.4) (Table 1). Compared with 1990, the age-
standardized prevalence of glaucoma-related blindness was reduced from 0.2% (95%UI: 0.1,
0.2) to 0.1% and the prevalence of glaucoma-relatedMSVI increased from 0.2% (95%UI: 0.2,
0.3) to 0.3% (Tables 1 and 2).
With respect to sex, the age-standardized prevalence of glaucoma related blindness among
women (0.1%; 95%UI: 0.1, 0.2) and men (0.1%; 95%UI: 0.1, 0.2) did not differ. The same held
true for the age-standardized prevalence of MSVI due to glaucoma (0.3% (95%UI: 0.2, 0.4) in
women versus 0.3% (95%UI: 0.3, 0.4) in men).
Discussion
Glaucoma was the cause for blindness in 2.1 million people or 6.6% of overall 32.4 million
blind people globally in 2010, and glaucoma was the cause for MSVI in 4.2 million people or
2.2% of overall 191 million people visually impaired in 2010 [36]. These figures are lower than
those reported by Quigley and Broman who forecasted in 2005 that in 2010, bilateral glaucoma
related blindness would affect 8.4 million people [2]. Quigley and Broman discussed the differ-
ence between their estimate and an estimate of 4.4 million that was the most recent estimate at
the time by theWHO Vision Group published by Resnikoff et al. [40]. Quigley and Broman
argued that the difference was due to methodological issues given that blindness prevalence
surveys often assigned the most ‘‘treatable” disease as the primary cause of blindness. It is often
Table 2. (Continued)
Region Number of People Affected in
1990
Mean Difference in the Number
of People Affected 2010–1990
Age-Standardized
Prevalence in People
Aged 50+ Years in 1990
Percent of Blindness /
Visual Impairment by
Glaucoma in 1990
Mean Lower
Value
Upper
Value
Mean Lower
Value
Upper
Value
Mean Lower
Value
Upper
Value
Europe,
Western
MSVI 184746 121141 311166 67800 50552 173543 0,1% 0,1% 0,2% 2.3 (1.8, 3.0)
Latin America,
Andean
MSVI 22239 12032 34711 40340 24420 72423 0,5% 0,3% 0,8% 2.1 (1.4, 3.0)
Latin America,
Central
MSVI 97887 58316 148486 136178 99422 214090 0,5% 0,3% 0,8% 2.5 (1.9, 3.7)
Latin America,
Southern
MSVI 34980 20728 64235 28207 15458 74998 0,3% 0,2% 0,6% 2.4 (1.7, 3.7)
Latin America,
Tropical
MSVI 102190 51076 171029 148399 81791 249207 0,6% 0,3% 0,9% 2.7 (1.6, 4.5)
North Africa/
Middle East
MSVI 139327 87028 195413 275569 175683 506068 0,5% 0,3% 0,7% 1.4 (1.1, 1.9)
North America,
High Income
MSVI 67720 46918 122215 36384 21743 114448 0,1% 0,1% 0,1% 2.4 (1.7, 3.4)
Oceania MSVI 1130 572 1785 2259 1097 4881 0,3% 0,1% 0,4% 0.73 (0.51, 1.1)
Sub-Saharan
Africa, Central
MSVI 10799 5902 20538 15946 9048 41912 0,3% 0,1% 0,5% 1.0 (0.71, 1.5)
Sub-Saharan
Africa, East
MSVI 41593 30430 57934 64340 46276 102706 0,3% 0,2% 0,4% 0.95 (0.76, 1.2)
Sub-Saharan
Africa, Southern
MSVI 10997 7531 17821 13603 7677 32011 0,3% 0,2% 0,4% 1.5 (1.1, 2.3)
Sub-Saharan
Africa, West
MSVI 45875 30759 65282 83552 61647 157048 0,3% 0,2% 0,4% 0.93 (0.71, 1.3)
doi:10.1371/journal.pone.0162229.t002
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assumed that cataract is more treatable than glaucoma, which leads to an underestimation of
glaucoma blindness. In the recent analysis of global blindness, glaucoma ranked third together
with macular degeneration (both: 6.6% of all blind people globally) after cataract (33.4% of all
blind people globally) and undercorrection of refractive error (20.9%) in the list of the most
common causes of global blindness [36]. Glaucoma and macular degeneration ranked first in
the list of most common irreversible causes of blindness.With respect to MSVI, glaucoma
ranked fourth (2.2%) after undercorrection of refractive error (52.9% of all people with MSVI
globally), cataract (18.4%) and macular degeneration (2.2%) in the list of the most common
causes of MSVI worldwide. These data confirm previous studies and meta-analyses which
showed that glaucoma had a prominent ranking in the frequency list of causes for blindness
and visual impairment. In contrast to the previous landmark study by Quigley and Broman,
glaucoma was ranked third and fourth in our study as compared to being ranked second by
Quigley and Broman and more recently Pascolini et al. as cause for blindness worldwide [2,41].
The numbers however also show that on a global perspective, cataract and undercorrection of
refractive error are by far more prevalent as causes for blindness and MSVI. Only one out of 15
blind people was blind due to glaucoma, and only one out of 45 visually impaired people was
visually impaired due to glaucoma. These figures may suggest that from a public health of view,
providing adequate glasses for correction of refractive error and supplying cataract surgery to
the blind and visually impaired may be at least as important as glaucoma care. In the recent
meta-analysis of population-based studies by Tham and colleagues, the global prevalence of
glaucoma in the population aged 40 to 80 years was 3.54% (95% Credible Intervals, 2.09, 5.82),
and the number of individuals aged 40 to 80 years and affected by glaucoma worldwide was
64.3 million in the year 2013 [3]. These figures cannot directly be compared with the figures
found in our investigation since Tham´s study addressed the number of individuals affected by
glaucoma, independently of the stage of the disease, while our study assessed the number of
individuals visually impaired or blind due to glaucoma.
The percentage of blindness caused by glaucoma showed regional variations, with relatively
low figures in regions with relatively young populations such as South Asia and Sub-Saharan
Africa, and with relatively high figures in regions with relatively old populations such as the
high-income regions (Tables 1 and 2). It was due to the dependence of the prevalence of glau-
coma on age, while other causes for blindness and MSVI, namely undercorrection of refractive
error and, to a lesser degree, cataract occurred also in younger groups of the population. These
regional differences in the percentage of glaucoma as cause for blindness and MSVI remained
mostly unchanged in the period from 1990 to 2010, since the differences in the age structure
between the various world regions did not markedly change.
The global number of glaucoma blind increased by 0.8 million in the period from 1990 to
2010, although the age-standardized global prevalence of glaucoma related blindness in adults
aged 50+ years decreased from 0.2% to 0.1%. The worldwide demographic transition with
increasing population size, substantial increase in the average age in most regions and falling
death rates more than outweighed the decrease in the prevalence of glaucoma related blindness
so that the absolute numbers increased by 0.8 million or 62% from 1990 to 2010. The global
prevalence of glaucoma related MSVI increased from 0.2% to 0.3% from 1990 to 2010, leading
to marked increase in the absolute number of people visually impaired by glaucoma by 2.3 mil-
lion or 83% in the same period. These figures show that, despite the relatively low percentage
of glaucoma related blindness and MSVI on all causes of blindness and MSVI, an intensifica-
tion of measures to address the growing number of people blind or visually impaired by glau-
coma appears mandatory.
Expressed in percentage points, the age-standardized global prevalence of cataract, under-
corrected refractive error and trachoma showed marked declines between 1990 and 2010 as
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reported previously [35]. The age-standardized prevalence of glaucoma declined less (for blind-
ness) or even increased slightly (for MSVI). Similar findings were observed for the age-stan-
dardized prevalence of macular degeneration and diabetic retinopathy [35]. These
developments may indicate a shift in the relative importance of the various diseases as causes
for blindness and visual impairment, with a decrease for the major causes of cataract and
undercorrection refractive error, which are relatively easily, safely and cost efficiently treatable,
unlike diseases such as glaucoma, macular degeneration and diabetic retinopathy for which the
therapy takes considerably more time and effort with a markedly lower rate of success.
Globally and in all regions, a larger percentage of blindness and MSVI caused by cataract
and macular degeneration occurs in women than in men [36]. Globally, 36% of blindness
among women was caused by cataract versus 30% of blindness among men; for MSVI, the fig-
ures were 20% versus 16%, respectively. In a similar manner, macular degeneration caused
7.3% of blindness among women versus 5.5% of blindness among men [36]. The glaucoma
related blindness and MSVI did not show such marked disparities by sex in our study. This dif-
fers from the predictions of Quigley and Broman who estimated that 59% of all people with
glaucoma of any stage would be women in 2010.
Literature reviews published by theWHO and theWHO Prevention of Blindness and Deaf-
ness program have previously been used to make worldwide estimates of numbers of people
blind or with vision impairment. The latest of these studies included literature published in the
period from 2000 to 2010 [41]. That analysis was limited to three age groups, with no break-
down by sex, provision of a point estimate for 2010, or estimates for the sixWHO epidemiolog-
ical subregions within a more limited timeframe. Interestingly, the figures for the percentage of
blindness and MSVI caused by glaucoma did not markedly differ between Pascolini and Mar-
iotti´s study and our study (glaucoma related blindness: 2% versus 2.2%; glaucoma related
MSVI: 8% versus 6.0%) [41].
The present study forms part of a series of investigations on the prevalence and causes of
vision loss in different world regions and on the number of individuals affected by MSVI and
blindness caused by the major disorders of under-correction of refractive error, cataract, macu-
lar degeneration, diabetic retinopathy and glaucomatous optic neuropathy [42–51]. Applying
the same statistical method (DisMod-MR) as the previous investigation, the present study
addressed the number of individuals affected by glaucoma as cause for their MSVI or blindness.
These figures may be of interest and help for politicians to direct financial means for the
improvement of public health with respect to MSVI and blindness and to direct financial sup-
port for research in specific fields of medicine and in particular of ophthalmology. The previ-
ous studies of the series either assessed the worldwide prevalence of MSVI and blindness or
examined the number of people affected by the main ocular disorders except for glaucomatous
optic neuropathy.
The figure of 2.1 million individuals blind due to glaucoma and of 4.2 million individuals
visually impaired due to glaucoma (representing 6.6% of all blindness and 2.2% of all MSVI
worldwide) were lower than the figures of 10.8 million people blind and 35.1 million visually
impaired due to cataract (representing 33.4% of all blindness and 18.4% of all MSVI world-
wide), and also lower than the figures of 6.8 million people blind and 101.2 million people
vision impaired due to undercorrected refractive errors (representing 20.9% of all blindness
and 52.9% of all MSVI worldwide) [49,51]. The figures of glaucoma associated blindness and
MSVI were similar to the numbers of 2.1 million individuals blind and 6.0 million individuals
visually impaired due to macular diseases (representing 6.6% of all blindness and 3.1% of all
vision impairment) [48]. They were higher than the figures of 0.8 million people were blind
due to diabetic retinopathy and 3.7 million visually impaired due to diabetic retinopathy (2.6%
of all blindness and 1.9% of all MSVI worldwide) [50].
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The design of our study had potential limitations. First, as we discussed in our report of
global prevalence of vision loss, a significant limitation was that many country-years lacked
data, or there was only sub-national data available [36]. Relatively few national studies reported
vision impairment for all ages and for all causes. Second, some data sources did not present the
prevalence by age. By imputing age-specific cause fractions we were able to utilize this data
with the assumption that the age pattern of the vision impaired in the particular study matched
the modeled age pattern in the country where the study was conducted [36]. Third, the major-
ity of population-based studies within the database that reported on vision loss due to glau-
coma did not disaggregate their reported findings into glaucoma diagnostic subtypes such as
open-angle glaucoma and angle-closure glaucoma, therefore it was not possible to differentiate
between glaucoma subtypes in our analysis. Fourth, protocol dictated that population-based
studies will report one cause as the principal cause for an individual examined in that individ-
ual study, so that causal prevalence can be calculated. In situations where multiple disorders
contribute equally to visual loss, only the ‘‘most easily preventable” or the ‘‘most readily cur-
able” cause is usually recorded [52]. This approach can underestimate the impact of diseases
such as diabetic retinopathy and glaucoma when a study participant presents with cataract,
while underestimating cataract burden when study participants also have an uncorrected
refractive error [53]. Finally, the relatively small sample size of some studies meant that the
confidence intervals of cause-specific prevalence estimates were relatively large. Our methods
did however take sample size into account, so small sample size studies had less influence on
the estimates than larger studies. Strengths of this study included the large amount of popula-
tion-based data accessed and utilized and the trend analysis of causes of vision impairment and
blindness, usage of non-linear age trends and modeling of data that were not reported by age,
systematic quantitative analysis and reporting of uncertainty intervals. The large size of net-
work of ophthalmologic researchers involved in first identification and then evaluation of data
sources allowed access to unpublished materials and permitted us to obtain additional unpub-
lished data from study investigators who had only published summary data, to evaluate all the
major vision impairment studies, and to include only studies that met specific inclusion criteria
regarding population representativeness and clear description and definition of visual acuity
procedures.
Conclusion
In conclusion, in 2010, 2.1 million people were blind and 4.2million people were visually impaired
due to glaucoma. The number of people blind and visually impaired due to glaucoma increased by
0.8 million people or 62% and by 2.3 million people or 83%, respectively, in the period from 1990
to 2010. The contribution of glaucoma to total blindness andMSVI was higher in high-income
regions with relatively older populations. One out of 15 blind people was blind due to glaucoma,
and one out of 45 visually impaired people was visually impaired due to glaucoma.
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